Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

摘要

This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.